KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Finished Goods (2016 - 2022)

Bio-Rad Laboratories (BIO) has disclosed Finished Goods for 14 consecutive years, with $309.9 million as the latest value for Q2 2022.

  • Quarterly Finished Goods fell 6.18% to $309.9 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $309.9 million through Jun 2022, down 6.18% year-over-year, with the annual reading at $312.6 million for FY2021, 8.97% down from the prior year.
  • Finished Goods for Q2 2022 was $309.9 million at Bio-Rad Laboratories, up from $306.0 million in the prior quarter.
  • The five-year high for Finished Goods was $354.1 million in Q1 2018, with the low at $298.3 million in Q4 2019.
  • Average Finished Goods over 5 years is $327.5 million, with a median of $331.6 million recorded in 2018.
  • The sharpest move saw Finished Goods fell 9.81% in 2019, then grew 15.12% in 2020.
  • Over 5 years, Finished Goods stood at $330.8 million in 2018, then fell by 9.81% to $298.3 million in 2019, then rose by 15.12% to $343.4 million in 2020, then fell by 8.97% to $312.6 million in 2021, then decreased by 0.88% to $309.9 million in 2022.
  • According to Business Quant data, Finished Goods over the past three periods came in at $309.9 million, $306.0 million, and $312.6 million for Q2 2022, Q1 2022, and Q4 2021 respectively.